INDIANAPOLIS, Sept. 15, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will host a webcast on September 24 to discuss data from EMPA-REG OUTCOME®, a long-term clinical trial investigating cardiovascular (CV) outcomes for Jardiance® (empagliflozin) in more than 7,000 adults with type 2 diabetes at high risk for CV events. Detailed study results will be presented on Thursday, September 17 at the 51st European Association for the Study of Diabetes (EASD) Annual Meeting in Stockholm, Sweden. JARDIANCE is part of the Boehringer Ingelheim and Lilly Diabetes Alliance.
The webcast on September 24 will begin at 10:00 a.m. Eastern Daylight Time. A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website at http://investor.lilly.com/events.cfm. A replay will be available for approximately one week.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels. P-LLY
SOURCE Eli Lilly and Company